ACHP Recommendations to Strengthen CMS Drug Price Negotiation Guidance for 2028
ACHP strongly supports the inclusion of Medicare Part B drugs and the renegotiation of previously selected drugs from 2026 and 2027.
Tag: drug pricing
Biosimilars: Expanding Drug Availability And Cutting Costs
ACHP calls on Congress to increase access to biosimilars by redefining interchangeability requirements and addressing outdated regulations, skewed incentives and PBM practices that intentionally slow their adoption.
ACHP Statement on “Most-Favored-Nation” Rx Pricing Executive Order
ACHP released a statement on the most-favored-nation prescription drug pricing executive order.
ACHP Statement on Drug Pricing
ACHP released a statement on drug pricing.
Ending the Allure of Drug Advertising
ACHP calls on Congress to curb direct-to-consumer (DTC) drug ad dominance. Patients should be able to access affordable, necessary medications, rather than being swayed by misleading marketing tactics.
